This morning, we announced strong results for Q4 and the full year 2012, reflecting successful execution on our mission to develop and deliver life-transforming therapies for patients with disorders that are severe, life-threatening, and also ultra-rare. Over the past year, we have significantly grown our commercial operations in existing and new
(
Read more... )
Comments 1
Reply
Leave a comment